Literature DB >> 31978213

Utility of serum free light chain ratio in response definition in patients with multiple myeloma.

Nadine Abdallah1, Prashant Kapoor1, David L Murray2, Francis K Buadi1, David Dingli1, Angela Dispenzieri1, Morie A Gertz1, Ronald S Go1, Wilson I Gonsalves1, Suzanne R Hayman1, Taxiarchis V Kourelis1, Martha Q Lacy1, Nelson Leung1,3, John A Lust1, Eli Muchtar1, Rahma Warsame1, Robert A Kyle1, S Vincent Rajkumar1, Shaji K Kumar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31978213      PMCID： PMC6988402          DOI： 10.1182/bloodadvances.2019001099

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  14 in total

1.  The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios.

Authors:  Seema Singhal; Eric Vickrey; Jairam Krishnamurthy; Veerpal Singh; Sharon Allen; Jayesh Mehta
Journal:  Blood       Date:  2009-05-01       Impact factor: 22.113

2.  Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.

Authors:  Jakub Radocha; Luděk Pour; Tomáš Pika; Vladimír Maisnar; Ivan Špička; Evžen Gregora; Marta Krejčí; Jiří Minařík; Kateřina Machálková; Jan Straub; Petr Pavlíček; Roman Hájek; Pavel Žák
Journal:  Eur J Haematol       Date:  2015-04-21       Impact factor: 2.997

Review 3.  Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.

Authors:  Asher A Chanan-Khan; Sergio Giralt
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

4.  Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma.

Authors:  Kamal Kant Singh Abbi; Margarida Silverman; Umar Farooq; Annick Tricot; Lindsey Dozeman; Kalyan Nadiminti; Matthew D Krasowski; Guido J Tricot
Journal:  Br J Haematol       Date:  2016-05-12       Impact factor: 6.998

5.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

6.  Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Authors:  Joaquín Martínez-López; Bruno Paiva; Lucía López-Anglada; María-Victoria Mateos; Teresa Cedena; María-Belén Vidríales; María Auxiliadora Sáez-Gómez; Teresa Contreras; Albert Oriol; Inmaculada Rapado; Ana-Isabel Teruel; Lourdes Cordón; María Jesús Blanchard; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Cecilia Cueto-Felgueroso; Alberto Orfao; Joan Bladé; Jesús F San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2015-06-18       Impact factor: 22.113

Review 7.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

8.  Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.

Authors:  José Luis García de Veas Silva; Carmen Bermudo Guitarte; Paloma Menéndez Valladares; Johanna Carolina Rojas Noboa; Krysta Kestler; Rafael Duro Millán
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

9.  Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

Authors:  Lucia Lopez-Anglada; Cecilia Cueto-Felgueroso; Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Ana Lopez de la Guia; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Jose Mariano Hernandez; Miquel Granell; Francisco Javier Peñalver; Ramon Garcia-Sanz; Juan Besalduch; Yolanda Gonzalez; Rafael Benigno Martinez; Miguel Teodoro Hernandez; Norma C Gutierrez; Paloma Puerta; Antonio Valeri; Bruno Paiva; Joan Blade; Maria-Victoria Mateos; Jesus San Miguel; Juan Jose Lahuerta; Joaquin Martinez-Lopez
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

10.  Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.

Authors:  M Hasib Sidiqi; Mohammed A Aljama; Dragan Jevremovic; William G Morice; Michael Timm; Francis K Buadi; Rahma Warsame; Martha Q Lacy; Angela Dispenzieri; David Dingli; Wilson I Gonsalves; Shaji Kumar; Prashant Kapoor; Taxiarchis Kourelis; Nelson Leung; William J Hogan; Morie Gertz
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941
View more
  3 in total

1.  A comparison of the efficacy and safety of ixazomib and lenalidomide combined with dexamethasone in the treatment of multiple myeloma.

Authors:  Zhipan Zheng; Kai Lin
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 2.  Measurable residual disease in multiple myeloma: ready for clinical practice?

Authors:  Leire Burgos; Noemi Puig; Maria-Teresa Cedena; María-Victoria Mateos; Juan José Lahuerta; Bruno Paiva; Jesús F San-Miguel
Journal:  J Hematol Oncol       Date:  2020-06-22       Impact factor: 17.388

3.  Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study.

Authors:  Danilo De Novellis; Raffaele Fontana; Angela Carobene; Bianca Serio; Idalucia Ferrara; Maria Carmen Martorelli; Laura Mettivier; Roberto Guariglia; Serena Luponio; Immacolata Ruggiero; Matteo D'Addona; Tiziana Di Leo; Valentina Giudice; Carmine Selleri
Journal:  Biomedicines       Date:  2022-07-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.